The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.

PURPOSE: The relationship between prostate-specific antigen (PSA) level and prostate cancer risk remains subject to fundamental disagreements. We hypothesized that the risk of prostate cancer on biopsy for a given PSA level is affected by identifiable characteristics of the cohort under study. EXPER...

Full description

Bibliographic Details
Main Authors:	Vickers, A, Cronin, A, Roobol, M, Hugosson, J, Jones, J, Kattan, M, Klein, E, Hamdy, F, Neal, D, Donovan, J, Parekh, D, Ankerst, D, Bartsch, G, Klocker, H, Horninger, W, Benchikh, A, Salama, G, Villers, A, Freedland, S, Moreira, D, Schröder, F, Lilja, H
Format:	Journal article
Language:	English
Published:	2010

Similar Items

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.
by: Roobol, M, et al.
Published: (2012)

Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
by: Ankerst, D, et al.
Published: (2014)

Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
by: Ankerst, D, et al.
Published: (2012)

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France.
by: Benchikh, A, et al.
Published: (2010)

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
by: Vickers, A, et al.
Published: (2010)

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France
by: Villers Arnauld, et al.
Published: (2010-11-01)

Screening for prostate cancer.
by: Carlsson, S, et al.
Published: (2012)

Screening for prostate cancer: To the editor
by: Carlsson, S, et al.
Published: (2012)

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
by: Vickers, A, et al.
Published: (2009)

Screening for prostate cancer: early detection or overdetection?
by: Vickers, A, et al.
Published: (2012)

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
by: Vickers, A, et al.
Published: (2010)

Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.
by: Carlsson, S, et al.
Published: (2012)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
by: Vickers, A, et al.
Published: (2010)

Screening for prostate cancer. The case against.
by: Donovan, J, et al.
Published: (2005)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
by: Lilja, H, et al.
Published: (2008)

Prostate cancer: screening approaches
by: Donovan, J, et al.
Published: (2005)

Prostate cancer: screening approaches.
by: Donovan, J, et al.
Published: (2005)

10-year outcomes in localized prostate cancer.
by: Hamdy, F, et al.
Published: (2017)

Prostate cancer detection in men aged 45-49 years in the UK protect (prostate testing for cancer and treatment) trial
by: Hamdy, F, et al.
Published: (2006)

Screening for prostate cancer remains controversial.
by: Neal, D, et al.
Published: (2009)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden.
by: Vickers, A, et al.
Published: (2008)

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.
by: Savage, C, et al.
Published: (2010)

10-year outcomes in localized prostate cancer: Authors' reply
by: Hamdy, F, et al.
Published: (2017)

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.
by: Gupta, A, et al.
Published: (2010)

The protecT (prostate testing for cancer and treatment) study: Evaluating screening and treatment of clinically localised prostate cancer in the UK
by: Hamdy, F, et al.
Published: (2006)

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
by: Vickers, A, et al.
Published: (2010)

Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?
by: Macefield, R, et al.
Published: (2009)

Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
by: Brindle, L, et al.
Published: (2006)

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy.
by: Avery, K, et al.
Published: (2012)

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy
by: Avery, K, et al.
Published: (2012)

Increase in percent free prostate-specific antigen in men with chronic kidney disease.
by: Bruun, L, et al.
Published: (2009)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study
by: Vickers, A, et al.
Published: (2010)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
by: Vickers, A, et al.
Published: (2010)

Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring (Corrigendum) (Nature Reviews Cancer (2008) 8, (268-278))
by: Lilja, H, et al.
Published: (2008)

ASSOCIATION OF ANTHROPOMETRIC AND LIFESTYLE FACTORS WITH PROSTATE SPECIFIC ANTIGEN (PSA) TRAJECTORIES IN MEN WITH LOCALISED PROSTATE CANCER UNDERGOING ACTIVE MONITORING
by: Burton, A, et al.
Published: (2011)

Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer.
by: Moore, A, et al.
Published: (2009)

Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.
by: Bruun, L, et al.
Published: (2005)

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
by: Aus, G, et al.
Published: (2004)

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.
by: Lilja, H, et al.
Published: (2011)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
by: Scardino Peter T, et al.
Published: (2008-07-01)